Zahid, Mohammad U. http://orcid.org/0000-0003-4893-4462
Waguespack, Matthew
Harman, Rebecca C.
Kercher, Eric M.
Nath, Shubhankar
Hasan, Tayyaba http://orcid.org/0000-0003-0871-6057
Rizvi, Imran
Spring, Bryan Q. http://orcid.org/0000-0001-7332-7707
Enderling, Heiko http://orcid.org/0000-0002-9696-6410
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01CA280849, U01CA244100, U01 CA280849, R01 CA226855)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 5 February 2024
Revised: 22 August 2024
Accepted: 28 August 2024
First Online: 11 September 2024
Competing interests
: HE receives funding and salary support related to this project from: NIH/NCI Physical Sciences in Oncology Network (U01CA244100 and U01CA280849). BQS receives funding and salary support related to this project from: NIH/NCI Physical Sciences in Oncology Network U01CA280849 and NIH/NCI grant R01CA226855, and unrelated to this project from: NIH/NCI grants R21CA263452 and P01CA084203. BQS and EMK are scientific founders of NIRA Biosciences and shareholders of Alys Pharmaceuticals. No potential conflicts of interest were disclosed by the other authors.